| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/29/2004 | US20040082558 Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity |
| 04/29/2004 | US20040082557 Methods for treating estrogen-dependent disorders |
| 04/29/2004 | US20040082556 Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use |
| 04/29/2004 | US20040082555 Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders |
| 04/29/2004 | US20040082554 Drug abuse, schizophrenia, Parkinson's disease, cognition activators |
| 04/29/2004 | US20040082553 Novel florfenicol-type antibiotics |
| 04/29/2004 | US20040082552 Synergistic mixture; induction mutation; viricides; therapy for drug resistancee |
| 04/29/2004 | US20040082551 Novel pyrazoles and their use as p38 kinase inhibitors |
| 04/29/2004 | US20040082549 Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections |
| 04/29/2004 | US20040082548 Cardiovascular disorders; Alzheimer's disease; anticholesterol agents |
| 04/29/2004 | US20040082547 Prevent thrombosis; anticholesterol agents; cardiovascular disorders; anticancer agents |
| 04/29/2004 | US20040082545 Transferring sodium hydroxide solution to container; osteoporosis, antitumor agents |
| 04/29/2004 | US20040082543 Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain |
| 04/29/2004 | US20040082542 Useful as modulators of interaction between receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, beta-amyloid and amphoterin |
| 04/29/2004 | US20040082541 Tuberculosis therapy; drug delivery systems prepared by grinding under solid state conditions of beta-Cyclodextrin and Rifampicin |
| 04/29/2004 | US20040082540 Use of a mixture of sodium hyaluronate and chondroitin sulfate for the treatment of osteoarthritis |
| 04/29/2004 | US20040082539 Extracting naturally occurring carbohydrate glucan from microorganisms; use in treatment of skin ulceration or bone fracture or enhancement of fixation of implanted orthopaedic devices, prevention/treatment of ultraviolet light skin damage |
| 04/29/2004 | US20040082538 Adjuvants and processes to induce a specific type of immune response |
| 04/29/2004 | US20040082536 Comprised of vitamins A, C, D, E, K, B1, B2, niacinamide, vitamin B6, vitamin B12, biotin, pantothenic acid, iron, iodine, magnesium, zinc, selenium, copper, chromium, potassium, choline, lycopene, coenzyme q-10 |
| 04/29/2004 | US20040082534 Treatment of melanoma by reduction in clusterin levels |
| 04/29/2004 | US20040082532 Antifungal therapeutic targets |
| 04/29/2004 | US20040082528 Pulsatillae radix root is known to have effects of removing heat from the blood and detoxifying; it has also been used as antiinflammatory, astringent, hemostatic and antidiarrhea agents |
| 04/29/2004 | US20040082527 Selected from the group of form D and E, F, G, J, M in the absence of azithromycin dihydrate, N, O, P, Q, and R; nuclear magnetic resonance spectrum analysis; bactericides; antiprotozoa agents; infections of mammals, birds and fish; drug resistance |
| 04/29/2004 | US20040082526 11,12 gamma lactone ketolides and pharmaceutically acceptable salts and solvates thereof, for use in therapy or prophylaxis of systemic or topical bacterial infections in humans or animals |
| 04/29/2004 | US20040082524 Use of aivlosin, 3-O-acetyl-4''-O-isovaleryl-tylosin and pharmacologically acceptable derivatives; treatment of necrotic enteritis in poultry and Lawsonia infections, Mycoplasma diseases and swine dysentery in pigs |
| 04/29/2004 | US20040082523 Composition for the prevention of osteoporosis comprising a combination of isoflavones and polyunsaturated fatty acids |
| 04/29/2004 | US20040082522 Use of DHEA and DHEA-sulfate for the treatment of chronic obstructive pulmonary disease |
| 04/29/2004 | US20040082521 Uses variety of liposomal-digitalis glycoside compositions; also provides protein-stabilized nanoparticle formulations containing liposomal-digitalis glycosides such as Oleandrin, digitoxin, and digoxin with reduced toxicity |
| 04/29/2004 | US20040082520 Comprising an alkyl-polyglycoside surfactant and a medicament for inhalation |
| 04/29/2004 | US20040082519 Method of treating and diagnosing sleep disordered breathing and means for carrying out the method |
| 04/29/2004 | US20040082517 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 04/29/2004 | US20040082514 Methods for treatment of helicobacter pylori-associated disorders |
| 04/29/2004 | US20040082510 Pyk2 phosphorylation by her3 induces tumor invasion |
| 04/29/2004 | US20040082504 Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases |
| 04/29/2004 | US20040082502 Method for treating wounds to promote healing |
| 04/29/2004 | US20040082500 For decreasing levels of plasma homocysteine; comprises dextromethorphan (DM)/folic acid/vitamins B6/12 |
| 04/29/2004 | US20040082499 Perturbed membrane-binding compounds |
| 04/29/2004 | US20040082498 Comprises heat shock protein 90 (Hsp 90) chaperone inhibitors; for topical administration |
| 04/29/2004 | US20040082497 For treatment of growth hormone deficiency/polycystic ovary syndrome autoimmune/inflammatory disease |
| 04/29/2004 | US20040082496 For the treatment of body weight disorders (obesity/anorexia/ bulemia/cachexia) |
| 04/29/2004 | US20040082052 Crystal structure |
| 04/29/2004 | US20040082037 Antiproliferative agents of vascular smooth muscles |
| 04/29/2004 | US20040081982 Neocentromere-based mini-chromosomes or artificial chromosomes |
| 04/29/2004 | US20040081976 Genomic screen for epigenetically silenced tumor suppressor genes |
| 04/29/2004 | US20040081968 Method and mixture for curing autoimmune disease |
| 04/29/2004 | US20040081958 Identification and use of molecular markers indicating cellular reprogramming |
| 04/29/2004 | US20040081715 Cholesterol reducing confectionery comprising a cocoa procyanidin monomer and/or oligomer and a sterol and/or stanol based cholesterol lowering agent |
| 04/29/2004 | US20040081714 Cosmetic and/or pharmaceutical preparations |
| 04/29/2004 | US20040081713 Breath freshening and oral cleansing product with magnolia bark extract |
| 04/29/2004 | US20040081712 Soy protein, phytoestrogens and dietary fibres and compositions |
| 04/29/2004 | US20040081711 alpha-Glucosidase inhibitors from a natural source |
| 04/29/2004 | US20040081709 Treatment of Alzheimer's disease (AD) and senile dementia of the Alzheimer's type (SDAT) |
| 04/29/2004 | US20040081708 Oral administration of an effective amount of N-acetyl-L-glutamine |
| 04/29/2004 | US20040081700 Partial doses of the active ingredient can accurately and reliably dispensed from the bulk formulations of proton pump inhibitor microgranules suspended in sufficiently viscous liquid |
| 04/29/2004 | US20040081699 Quickly disintegrate in aqueous media |
| 04/29/2004 | US20040081697 Single daily dose of insulin sensitizer and another antidiabetic agent, such as an alpha glucosidase inhibitor, a biguanide or an insulin secretagogue |
| 04/29/2004 | US20040081696 Irradiation directly transfers the energy required to evaporate the solvent to the drug coated particle |
| 04/29/2004 | US20040081694 Melt-extruded orally administrable opioid formulations |
| 04/29/2004 | US20040081693 Capable of releasing the drug at a constant rate following zero order kinetics for 24 hours or more |
| 04/29/2004 | US20040081687 Cholesterol group is linked to the optional linker group via a carbamoyl linkage and then linked to carbohydrate |
| 04/29/2004 | US20040081685 Plurality of patch units connected along one or more borders divisible into respective units allowing dosage to be adjusted |
| 04/29/2004 | US20040081684 Topical delivery of antifungal agents |
| 04/29/2004 | US20040081683 Transdermal delivery system |
| 04/29/2004 | US20040081682 Crystal-free transdermal formulations of the more active (-)-enantiomer of rolipram that are easy to administer |
| 04/29/2004 | US20040081678 Dietary regimen that decreases overactive sympathetic tone and also increases dopaminergic tone; simple sugars and/or high glycemic index carbohydrates are not provided with fats at a ratio greater than 1 to 4; L-Dopa containing foods |
| 04/29/2004 | US20040081677 Gel formulations of hydroxypyridone derivatives, which contain solvents and hydrophilic gel-forming agents make possible a high release of the active compound |
| 04/29/2004 | US20040081675 Cosmetic formulations containing flavonoid derivatives |
| 04/29/2004 | US20040081674 For the treatment of dry, sensitive skin. Despite being free from such ingredients as perfumes, preservatives, colorings, plant extracts, PEGs, cetylstearyl alcohol, lanolin alcohol, lower alcohols and proteins |
| 04/29/2004 | US20040081672 Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging |
| 04/29/2004 | US20040081671 Liquid dosage forms of non-enterically coated acid-labile drugs |
| 04/29/2004 | US20040081670 Method for producing an active ingredient concentrate, and an active ingredient concentrate |
| 04/29/2004 | US20040081668 For the treatment of a hyperpigmented skin condition |
| 04/29/2004 | US20040081667 Compositions and methods for treating and preventing infection |
| 04/29/2004 | US20040081665 Chlorella preparations exhibiting immunomodulating properties |
| 04/29/2004 | US20040081664 Oral delivery of a botanical |
| 04/29/2004 | US20040081650 Inflammatory mediator antagonists |
| 04/29/2004 | US20040081642 Methods of treating vascular diseases characterized by nitric oxide insufficiency related applications |
| 04/29/2004 | US20040081631 Cosmetic composition for skin whitening comprising senkyunolide a as active ingredient |
| 04/29/2004 | US20040081628 Tinting, coloring skins; radiation resistance; sunscreen agents |
| 04/29/2004 | US20040081626 Liquid mixture containing active materials; suspension drops in carrier gas; drug delivery; asthma therapy |
| 04/29/2004 | US20040081625 Nasal formulations for the treatment of allergies |
| 04/29/2004 | US20040081624 Mixture containing high volatility carrier; vaporization; mixing with air |
| 04/29/2004 | US20040081622 Absorption, fluorescence of light; diagnosis of kidney, heart diseases |
| 04/29/2004 | US20040081620 Measurement anticoagulant |
| 04/29/2004 | US20040079671 Medicinal product packaging |
| 04/29/2004 | DE10296849T5 Verfahren zur Einkapselung eines Wirkstoffes A process for encapsulation of an active ingredient |
| 04/29/2004 | DE10294485T5 Mit Mnk-Kinase homologe Proteine, die in die Regulation der Energiehomöostase und den Organellenmetabolismus involviert sind Mnk homologous proteins with kinase, that are involved in the regulation of energy homeostasis and the metabolism organelle |
| 04/29/2004 | DE10248309A1 Delayed release analgesic formulations, comprising 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol in hydrophilic or hydrophobic polymer matrix |
| 04/29/2004 | DE10246340A1 Kombinationspräparat aus Hyaluronsäure und mindestens einem Lokalanästhetikum und dessen Verwendung Combination preparation of hyaluronic acid and at least one local anesthetic and its use |
| 04/29/2004 | DE10236262A1 Polyisoprenyl-benzophenon-Derivate, Verfahren zu ihrer Herstellung und Verwendung desselben Polyisoprenylbenzophenone derivatives thereof processes for their preparation and use |
| 04/29/2004 | CA2783175A1 Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives |
| 04/29/2004 | CA2771725A1 Solid preparation comprising a non-toxic base and a proton pump inhibitor |
| 04/29/2004 | CA2737851A1 Controlled release preparation |
| 04/29/2004 | CA2588083A1 Selective androgen receptor modulators and methods of use thereof |
| 04/29/2004 | CA2542620A1 Method of treating snoring and other obstructive breathing disorders |
| 04/29/2004 | CA2503325A1 Methods for treatment of helicobacter pylori-associated disorders |
| 04/29/2004 | CA2503075A1 Derivatives of n-phenylanthranilic acid and 2-benzimidazolon as potassium channel and/or cortical neuron activity modulators |
| 04/29/2004 | CA2502787A1 Treating alcohol and or substance abuse by antagonizing .alpha. 2 adrenergic receptors with weak dopamine blocking |
| 04/29/2004 | CA2502644A1 Reverse-turn mimetics and composition and methods relating thereto |
| 04/29/2004 | CA2502510A1 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor |